Three-way user fee trigger finds industry detractors
This article was originally published in Clinica
The US $225m user fee programme hinges on an intricately-balanced three-way pact between the FDA, Congress and industry, writes Karen Riley.
You may also be interested in...
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.